Streetbeat News

Products Services

NVCR

Novocure announced that an exploratory subgroup analysis of the Phase 3 ENGOT-ov50/GOG-3029/INNOVATE-3 trial has been selected for presentation at the European Society on Gynecological Oncology 2024 Congress. The analysis found that PLD-naïve patients receiving TTFields therapy and paclitaxel had a median overall survival of 16.0 months, compared to 11.7 months for those treated with paclitaxel alone.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:16 am

GLUE

Monte Rosa Therapeutics announced its first development candidate from the NEK7 program, MRT-8102, targeting inflammatory diseases driven by Interleukin-1β and the NLRP3 inflammasome.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:14 am

PERI

Perion Network Ltd. has announced a partnership with Way.io to enter the world's largest Digital Out-of-Home (DOOH) advertising market, valued at $5.2 billion. This strategic move aims to leverage Way.io's expertise and presence in the DOOH market to expand Perion's advertising capabilities and reach.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:12 am

TVTX

Travere Therapeutics has submitted a Supplemental New Drug Application (sNDA) to the FDA for full approval of FILSPARI, aimed at treating IgA Nephropathy. This step could mark a significant advancement in the treatment options available for this kidney disease.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:12 am

VTYX

Ventyx Biosciences announced updates on its clinical pipeline, including positive Phase 1 results for VTX3232, topline Phase 2 data for VTX2735, and supportive early Phase 2 data for VTX002. The company plans to initiate Phase 2a trials for VTX3232 in Parkinson's disease and obesity by H2 2024, evaluate VTX2735 in cardiovascular diseases, and seek partnerships for VTX002's Phase 3 trial in ulcerative colitis. Ventyx also expects its current funds to last into at least H2 2026 due to pipeline reprioritization and recent financing.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:11 am

PLUR

Pluri has received patent approval for its groundbreaking 3D bioreactor technology, titled 'A System for 3D Cultivation of Plant Cells and Methods of Use'. This technology facilitates efficient cultivation of plant cells for diverse applications, including sustainable agriculture and healthcare solutions.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:11 am

RDHL

Redhill Biopharma announced the issuance of a new U.S. patent for Talicia, a fixed-dose combination of amoxicillin, omeprazole, and rifabutin for Helicobacter pylori treatment. This patent extends protection for Talicia until February 12, 2034.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:10 am

LXRX

Lexicon Pharmaceuticals is preparing to resubmit a New Drug Application (NDA) for Sotagliflozin, aimed at treating Type 1 Diabetes, following constructive feedback from the FDA. This move could potentially lead to the approval of a new treatment option for patients with Type 1 Diabetes.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:08 am

NRIX

The FDA has lifted the partial clinical hold on Nurix Therapeutics' NX-2127 Phase 1 trial, initially placed due to a transition to an improved manufacturing process. Nurix plans to resume enrollment with a new drug substance in the ongoing Phase 1a/1b trial.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:02 am

REGN

Regeneron Pharmaceuticals has announced that the FDA has extended the approval of its drug Praluent to include treatment for patients aged 8 and older with heterozygous familial hypercholesterolemia (HeFH).

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 11:02 am